» Articles » PMID: 38854472

A Combination of Myokines and Genistein Suppresses Cancer Stemness in MCF-7 Human Breast Cancer Cells

Overview
Journal Nutr Res Pract
Date 2024 Jun 10
PMID 38854472
Authors
Affiliations
Soon will be listed here.
Abstract

Background/objectives: Breast cancer is considered a serious health issue worldwide and is influenced by risk factors, including physical inactivity and unhealthy diet. Myokines secreted by muscles during physical activity play a crucial role in cancer development and the immune system. Genistein (Gen), an isoflavone primarily in legumes, induces anti-cancer activity by regulating cancer stem cells (CSCs). Therefore, this study investigated the potential anti-cancer effect of a combination of myokine and Gen on the human breast cancer MCF-7 cells.

Materials/methods: MCF-7, a human breast cancer cell line, was used for study. The cell viability of MCF-7 cells was evaluated in response to treatment with myokines, irisin (Iri), oncostatin M (OSM), and Gen using the MTT assay. Clonogenic and sphere formation assays were used to evaluate the self-renewal capacity of breast CSCs. The mRNA expression levels of stem cell markers were analyzed in MCF-7 breast cancer cells.

Results: Administering Iri or OSM with Gen significantly inhibited the self-renewal capacity of MCF-7 cells. In addition, mRNA expression of breast CSC markers and , which are characteristic of CSCs, was suppressed by both myokine and Gen. However, combining Iri or OSM with Gen was the most effective treatment.

Conclusion: These results suggested that combining Iri or OSM with Gen has an additive effect on breast CSCs by regulating self-renewal capacity and expression of CSCs markers. Therefore, the combination of myokines and Gen may have the therapeutic potential for treating breast cancer and improving the quality of life of cancer patients.

Citing Articles

Molecular Mechanisms of Dietary Compounds in Cancer Stem Cells from Solid Tumors: Insights into Colorectal, Breast, and Prostate Cancer.

Filippi A, Deculescu-Ionita T, Hudita A, Baldasici O, Galateanu B, Mocanu M Int J Mol Sci. 2025; 26(2).

PMID: 39859345 PMC: 11766403. DOI: 10.3390/ijms26020631.

References
1.
Cebulski K, Nowinska K, Jablonska K, Romanowicz H, Smolarz B, Dziegiel P . Expression of Irisin/FNDC5 in Breast Cancer. Int J Mol Sci. 2022; 23(7). PMC: 8998925. DOI: 10.3390/ijms23073530. View

2.
Masjedi A, Hajizadeh F, Beigi Dargani F, Beyzai B, Aksoun M, Hojjat-Farsangi M . Oncostatin M: A mysterious cytokine in cancers. Int Immunopharmacol. 2020; 90:107158. DOI: 10.1016/j.intimp.2020.107158. View

3.
Li C, Ahlborn T, Kraemer F, Liu J . Oncostatin M-induced growth inhibition and morphological changes of MDA-MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway. Breast Cancer Res Treat. 2001; 66(2):111-21. DOI: 10.1023/a:1010614724664. View

4.
Diaz B, Almeida Gonzalez D, Gannar F, Perez M, de Leon A . Myokines, physical activity, insulin resistance and autoimmune diseases. Immunol Lett. 2018; 203:1-5. DOI: 10.1016/j.imlet.2018.09.002. View

5.
Banerjee S, Li Y, Wang Z, Sarkar F . Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008; 269(2):226-42. PMC: 2575691. DOI: 10.1016/j.canlet.2008.03.052. View